Press release from Companies

Publicerat: 2022-02-16 13:40:00

SelectImmune Pharma AB (publ): SelectImmune Pharma’s CMO and Board member Gabriela Godaly promoted to Professor at Lund University

Selectimmune Pharma is pleased to announce the promotion of its Chief Medical Officer (CMO) and Board member Dr. Gabriela Godaly to Professor of Clinical Microbiology at Lund University as of February 2022.

Dr. Godaly received her PhD in 2000 and has since developed a successful, well-funded research group, focusing on the area of tuberculosis and the development of new alternatives to antibiotics for treating these infections. The group studies the immune response, effects of vaccines and new treatment approaches. Dr. Godaly’s group has successfully developed a peptide-based therapy, characterized its effects in cellular models and performed effect studies in animal models, in collaboration with leading international experts. Dr. Godaly has also played an important role for the development of teaching programs for medical students and as member of different networks and policy committees in the medical faculty. 

Gabriela Godaly is a clinical trials expert, from work at Gambro AB as well as Lund University. This expertise is extremely valuable for SelectImmune Pharmas clinical trial program and Dr. Godaly was appointed Chief Medical Officer of SelectImmune Pharma in 2020. Dr. Gabriela Godaly has served on the Board of Directors of SelectImmune Pharma since 2019.

The professorship acknowledges the important contributions of Dr. Godaly and we are delighted by her success,” says Catharina Svanborg, Professor and Chairman of the board, SelectImmune Pharma.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49


Gabriela Godaly

CMO SelectImmune Pharma AB

Phone: +46 733 38 13 44


SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UVI) are one of the world’s most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.

Läs mer hos Cision
Läs mer om SelectImmune Pharma AB (publ)